Details

Autor(en) / Beteiligte

• Moncunill, Gemma
• Armand-Ugón, Mercedes
• Clotet-Codina, Imma
• Pauls, Eduardo
• Ballana, Ester
• Llano, Anuska
• Romagnoli, Barbara
• Vrijbloed, Jan W
• Gombert, Frank O
• Clotet, Bonaventura
• De Marco, Steve
• Esté, José A

Titel

Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026

Ist Teil von

• Molecular pharmacology, 2008-04, Vol.73 (4), p.1264-1273

Ort / Verlag

United States: American Society for Pharmacology and Experimental Therapeutics

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• We have studied the mechanism of action of Arg * -Arg-Nal 2 -Cys(1×)-Tyr-Gln-Lys-( d -Pro)-Pro-Tyr-Arg-Cit-Cys(1×)-Arg-Gly-( d -Pro) * (POL3026), a novel specific β-hairpin mimetic CXC chemokine receptor (CXCR)4 antagonist. POL3026 specifically blocked the binding of anti-CXCR4 monoclonal antibody 12G5 and the intracellular Ca 2+ signal induced by CXC chemokine ligand 12. POL3026 consistently blocked the replication of human immunodeficiency virus (HIV), including a wide panel of X4 and dualtropic strains and subtypes in several culture models, with 50% effective concentrations (EC 50 ) at the subnanomolar range, making POL3026 the most potent CXCR4 antagonist described to date. However, 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane (AMD3100)-resistant and stromal cell-derived factor-1α-resistant HIV-1 strains were cross-resistant to POL3026. Time of addition experiments and a multiparametric evaluation of HIV envelope function in the presence of test compounds confirmed the activity of POL3026 at an early step of virus replication: interaction with the coreceptor. Generation of HIV-1 resistance to POL3026 led to the selection of viruses 12- and 25-fold less sensitive and with mutations in gp120, including the V3 loop region. However, POL3026 prevented the emergence of CXCR4-using variants from an R5 HIV-1 strain that may occur in the presence of anti-HIV agents targeting CC chemokine receptor 5.